Lantheus Holdings, Inc. Q1 FY2026 earnings call

• Strong start to 2026 with solid performance across Polarify, Neuroseek, and DFINITY. 2026 is a year of commercial execution and regulatory milestones. - Priorities include maintaining PSMA PET market leadership and transitioning to Polarify TrueView, building momentum for Neuroseq, advancing late - stage clinical portfolio, and allocating capital with discipline. - FDA approved Polarify TrueView, extended PDUFA date for Octavi, and gave tentative approval for PNT - 2003. - Key pipeline updates: MK6240 has PDUFA date of Aug 13, Lantheus 2401 advancing towards registrational program.

Revenue for Q1 2026 was $377.3 million. Oncology (Polarify) contributed $240.9 million, down 6.5% YoY. Neurology (NeuroSeq) was $35.4 million. Cardiology (DFINITY) was $84.6 million, up 6.8% YoY. Strategic partnerships and other was $16.3 million, up 52.1%. Polarify had US volume increase ~5.8% YoY. NeuroSeq had 14.3% QoQ revenue growth. DFINITY had ~6.8% YoY revenue growth.

• Full - year 2026 revenue forecast remains at $1.4 to $1.45 billion. - EPS range is $5 to $5.25. - Remain vigilant to competitive environment, allow new CEO to own balance of the year, and expect modest volume growth.

• Q: On guidance, reiteration of guide assumes step down, is it conservatism, any incremental caution?

A: Prudent due to competitive environment, new CEO, and monitoring competitors. - Q: On PSMA pet market growth in 2026, A: Market growth in low teens, triangulated figure based on own results and competitor monitoring. - Q: On TrueView transition, when adopted and phase out of Polarify?

A: Geographically site - by - site conversion starting Q4, Polarify transitioned to TrueView, not phased out. - Q: Strategies for customer readiness for TrueView?

A: Ensure coverage, payment, coding in place, contractually prepare customers, and have operational steps for manufacturing. - Q: Pricing strategy with TPT for TrueView and impact on 2027?

A: Don't talk about pricing strategy, transitional pass - through is for traditional fee - for - service Medicare patients, 2027 seen as growth acceleration year. - Q: Other F - 18 or Gallium - 68 PSMA imaging agents entering market?

A: Continuously monitor, but no meaningful impact seen in next couple of months. - Q: Percentage of PF network with high - energy cyclotrons for TrueView?

A: ~70% of current PMS network for Polarify already have high - energy cyclotrons. - Q: Gross margins, normalized run rate or one - off?

A: Trailing toward higher end of 65 - 66% range, with one - off due to various factors. - Q: Process for PNT - 2003 tentative approval to full approval, included in guidance?

A: Final approval depends on Hatch - Waxman stay expiration, legal proceedings, and launch readiness; not in 2026 revenue guidance. - Q: On Polarify pricing pressure and guidance, A: Early in year, happy with first quarter results, prudent to stick with guidance due to CEO change. - Q: Neuroseq market share and attach rate to disease - modifying agents?

A: Fastest growing and second highest share in beta amyloid imaging market, benefiting from large expanding market, adoption of DMTs, and guidelines favoring earlier diagnostic usage.